SG Power signs deal with Lablink Enterprises to distribute Japanese firm's healthcare products in Pakistan

SG Power Limited has entered into a distribution agreement with Lablink Enterprises to distribute Nipro hospital products in Pakistan, marking another step in the company’s shift from power generation to the healthcare sector.

In a material information notice submitted to the Pakistan Stock Exchange (PSX) on July 8, the company said the agreement would support its broader strategy to expand its presence in Pakistan’s healthcare market.

Nipro Corporation, headquartered in Osaka, Japan, is a global healthcare and medical technology company with a history of more than seven decades. It develops, manufactures and supplies medical devices, pharmaceutical products and pharmaceutical packaging solutions. The company serves healthcare providers in more than 150 countries through its manufacturing, research and distribution network.

According to the disclosure, Nipro is recognised for its hospital products, including infusion therapy, vascular and other medical products.

Lablink Enterprises is the sole distributor of Nipro hospital products in Pakistan and has represented the brand locally for more than 15 years, supplying products to hospitals, healthcare institutions and clinical care providers across the country.

SG Power said the agreement provides a framework for distributing Nipro hospital products in Pakistan through an established local platform. It said the combination of Nipro’s product portfolio and Lablink Enterprises’ distribution network is expected to strengthen SG Power’s position in the medical devices sector and create a platform for future growth.

The latest agreement follows SG Power’s recent corporate restructuring. Earlier, the company increased its authorised share capital fourfold from Rs200 million to Rs800 million after completing the required legal and regulatory formalities, including payment of prescribed fees.

The company said the higher authorised capital would provide capacity for a proposed rights issue, subject to regulatory and corporate approvals.

SG Power has also applied to the PSX for reclassification from the Power Generation sector to the Pharmaceuticals sector, in line with its approved strategic transformation and revised principal line of business.

On June 29, 2026, the company announced completion of the required formalities to change its principal line of business from Power Generation Allied (Other) to Pharmaceutical Allied (Healthcare Sector).

Under the amended business scope, SG Power is authorised, subject to applicable laws and regulatory approvals, to import, export, manufacture, distribute, market, sell, rent, install, maintain and provide after-sales servicing of medical equipment, medical devices, hospital supplies and related healthcare products.

The revised scope also allows the company to manufacture and trade pharmaceutical, medicinal and allied products under its amended Memorandum of Association.